Schroder Investment Management Group Has $41.07 Million Position in Axon Enterprise, Inc $AXON

Key Points

• Schroder Investment Management Group cut its stake in Axon by 28.4% in Q3, selling 22,750 shares and leaving it with 57,235 shares worth about $41.07 million.
• Axon reported a strong quarter—EPS $2.15 vs. $1.60 estimate and revenue $796.7M (up 38.5% YoY)—but the stock faces valuation pressure (P/E ~340) and recent heavy insider selling, creating risk of short‑term profit‑taking despite analyst optimism and a consensus target well above current levels.

Schroder Investment Management Group cut its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 28.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,235 shares of the biotechnology company's stock after selling 22,750 shares during the quarter. Schroder Investment Management Group owned about 0.07% of Axon Enterprise worth $41,074,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after buying an additional 376,904 shares during the period. Geode Capital Management LLC boosted its position in shares of Axon Enterprise by 5.9% in the second quarter. Geode Capital Management LLC now owns 2,072,186 shares of the biotechnology company's stock valued at $1,713,332,000 after acquiring an additional 115,349 shares during the period. Jennison Associates LLC boosted its position in shares of Axon Enterprise by 53.8% in the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company's stock valued at $677,412,000 after acquiring an additional 330,213 shares during the period. Vestor Capital LLC grew its stake in shares of Axon Enterprise by 438,636.3% in the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company's stock valued at $690,170,000 after acquiring an additional 833,409 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Axon Enterprise in the second quarter valued at about $637,806,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

Analyst Ratings Changes

AXON has been the subject of several analyst reports. Morgan Stanley dropped their price objective on shares of Axon Enterprise from $713.00 to $675.00 and set an "overweight" rating for the company in a research note on Wednesday, February 25th. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Axon Enterprise in a report on Monday, December 29th. Wall Street Zen upgraded shares of Axon Enterprise from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Needham & Company LLC cut their price target on Axon Enterprise from $870.00 to $600.00 and set a "buy" rating for the company in a research note on Friday, February 20th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $762.93.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the transaction, the insider directly owned 55,588 shares of the company's stock, valued at $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Jennifer H. Mak sold 1,500 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the transaction, the chief accounting officer owned 12,240 shares of the company's stock, valued at approximately $7,019,028. This represents a 10.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 24,634 shares of company stock worth $13,803,095. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Stock Down 2.3%

Shares of NASDAQ AXON opened at $517.57 on Thursday. The stock has a market capitalization of $41.61 billion, a P/E ratio of 340.51, a PEG ratio of 11.31 and a beta of 1.46. The stock's fifty day moving average is $533.80 and its 200 day moving average is $613.08. Axon Enterprise, Inc has a 52 week low of $396.41 and a 52 week high of $885.91. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to analysts' expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. Axon Enterprise's revenue was up 38.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.08 earnings per share. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.